Dr. Natasha Martin
Natasha K. Martin , DPhil, is an Associate Professor in the Division of Global Public Health in the Department of Medicine at the University of California San Diego. She is also an Honorary Senior Lecturer at the University of Bristol. Dr. Martin is an infectious disease and economic modeler with over 15 years of experience modeling biological systems. She earned her doctoral degree in mathematical biology from the University of Oxford, and undergraduate degree in mathematics and biology from Stanford University. Following her doctorate, she worked as a postdoctoral fellow at the University of Bristol and London School of Hygiene and Tropical Medicine.
Dr. Martin’s work focuses on using dynamic epidemic modelling to evaluate the impact and cost-effectiveness of HIV, HCV, and HBV prevention interventions among high risk populations such as people who inject drugs, men who have sex with men, and incarcerated populations. She is one of the leading researchers examining the potential impact and cost-effectiveness of HCV treatment as prevention. Currently she is engaged in a number of HIV and HCV intervention evaluation trials in international settings such as Mozambique, India, Kenya, Ukraine, Mexico, Australia, and the UK.
- Martin NK, Hickman M, Hutchinson SJ, Goldberg DJ, and Vickerman P. Combination interventions to
prevent HCV transmission among people who inject drugs: modelling the impact of antiviral treatment, needle and syringe programmes, and opiate substitution therapy. Clinical Infectious Diseases 2013;57(suppl 2): S39-S45.
- Martin NK, Vickerman P, Grebely J, Hellard M, Hutchinson SJ, Lima VD, Foster GR, Dillon JF, Goldberg DJ, Dore GJ, and Hickman M. HCV treatment for prevention among people who inject drugs: modeling treatment scale-up in the age of direct-acting antivirals. Hepatology 2013;58(5):1598-1609
- Martin NK, Hickman M, Miners A, Hutchinson SJ, Taylor A, and Vickerman P. Cost-effectiveness of increasing HCV case-finding for people who inject drugs in specialist addiction services and prisons. BMJ Open 2013;3:e003153. doi:10.1136/bmjopen-2013-003153
- Martin NK, Vickerman P, Miners A, Foster GR, Hutchinson S, Goldberg D, and Hickman M. The cost-effectiveness of HCV antiviral treatment for injecting drug user populations. Hepatology 2012;55(1):49-57.
- Martin NK, Devine A, Eaton JW, Miners A, Hallett TB, Foster GR, Dore G, Easterbrook PJ, Legood R, Vickerman P. Modeling the impact of early antiretroviral treatment for adults coinfected with HIV and hepatitis B or C in South Africa. AIDS 2014;28(suppl 1):S35-S46
- Modeling Structural HIV Determinants in Substance Users and Related Populations. Co-PI (Natasha Martin, Steffanie Strathdee, Peter Vickerman). Funding Source: NIDA R01-DA03773
- HCV transmission among HIV positive men who have sex with men: modelling the UK epidemic and projecting the impact of HCV antiviral treatment for prevention. PI. Funding Source: Gilead Sciences.
- The impact and cost-effectiveness of HCV treatment in prison in the DAA era: modelling analyses in England and Scotland. PI. Funding Source: Gilead Sciences.
- Stratified Medicine to Optimise Treatment for Hepatitis C Virus Infection (STOP-HCV). Co-I (lead University of Oxford). Funding Source: UK Medical Research Council
- Ensuring access to the HCV treatment revolution for HCV/HIV coinfected patients in low and middle income countries. Co-I (lead Medicins Sans Fronteires) Funding source: UNITAID
- Surveillance and Treatment of Prisoners with Hepatitis C (STOP-C). Co-I (lead University of New South Wales, Australia). Funding Source: Australian National Health and Medical Research Council.